Impact  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
training  ||| S:10 E:19 ||| NN
status  ||| S:19 E:26 ||| NN
on  ||| S:26 E:29 ||| IN
LPS-induced  ||| S:29 E:41 ||| JJ
acute  ||| S:41 E:47 ||| JJ
inflammation  ||| S:47 E:60 ||| NN
in  ||| S:60 E:63 ||| IN
humans  ||| S:63 E:70 ||| NNS
The  ||| S:70 E:74 ||| DT
aim  ||| S:74 E:78 ||| NN
of  ||| S:78 E:81 ||| IN
the  ||| S:81 E:85 ||| DT
present  ||| S:85 E:93 ||| JJ
study  ||| S:93 E:99 ||| NN
was  ||| S:99 E:103 ||| VBD
to  ||| S:103 E:106 ||| TO
examine  ||| S:106 E:114 ||| VB
the  ||| S:114 E:118 ||| DT
impact  ||| S:118 E:125 ||| NN
of  ||| S:125 E:128 ||| IN
training  ||| S:128 E:137 ||| NN
status  ||| S:137 E:144 ||| NN
on  ||| S:144 E:147 ||| IN
the  ||| S:147 E:151 ||| DT
ability  ||| S:151 E:159 ||| NN
to  ||| S:159 E:162 ||| TO
induce  ||| S:162 E:169 ||| VB
a  ||| S:169 E:171 ||| DT
lipopolysaccharide  ||| S:171 E:190 ||| NN
( ||| S:190 E:191 ||| -LRB-
LPS ||| S:191 E:194 ||| NNP
) ||| S:194 E:195 ||| -RRB-
-induced  ||| S:195 E:204 ||| JJ
inflammatory  ||| S:204 E:217 ||| JJ
response  ||| S:217 E:226 ||| NN
systemically  ||| S:226 E:239 ||| NN
as  ||| S:239 E:242 ||| IN
well  ||| S:242 E:247 ||| RB
as  ||| S:247 E:250 ||| RB
in  ||| S:250 E:253 ||| IN
skeletal  ||| S:253 E:262 ||| JJ
muscle  ||| S:262 E:269 ||| NN
( ||| S:269 E:270 ||| -LRB-
SkM ||| S:270 E:273 ||| NNP
)  ||| S:273 E:275 ||| -RRB-
and  ||| S:275 E:279 ||| CC
adipose  ||| S:279 E:287 ||| JJ
tissue  ||| S:287 E:294 ||| NN
( ||| S:294 E:295 ||| -LRB-
AT ||| S:295 E:297 ||| NNP
)  ||| S:297 E:299 ||| -RRB-
in  ||| S:299 E:302 ||| IN
human  ||| S:302 E:308 ||| JJ
subjects ||| S:308 E:316 ||| NNS
.  ||| S:316 E:318 ||| .
Seventeen  ||| S:318 E:328 ||| JJ
young  ||| S:328 E:334 ||| JJ
( ||| S:334 E:335 ||| -LRB-
23.8  ||| S:335 E:340 ||| CD
±  ||| S:340 E:342 ||| CD
2.5  ||| S:342 E:346 ||| CD
yr  ||| S:346 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
age ||| S:352 E:355 ||| NN
)  ||| S:355 E:357 ||| -RRB-
healthy  ||| S:357 E:365 ||| JJ
male  ||| S:365 E:370 ||| JJ
subjects  ||| S:370 E:379 ||| NNS
were  ||| S:379 E:384 ||| VBD
included  ||| S:384 E:393 ||| VBN
in  ||| S:393 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
study  ||| S:400 E:406 ||| NN
with  ||| S:406 E:411 ||| IN
eight  ||| S:411 E:417 ||| CD
subjects  ||| S:417 E:426 ||| NNS
assigned  ||| S:426 E:435 ||| VBN
to  ||| S:435 E:438 ||| TO
a  ||| S:438 E:440 ||| DT
trained  ||| S:440 E:448 ||| NN
( ||| S:448 E:449 ||| -LRB-
T ||| S:449 E:450 ||| NN
)  ||| S:450 E:452 ||| -RRB-
group  ||| S:452 E:458 ||| NN
and  ||| S:458 E:462 ||| CC
nine  ||| S:462 E:467 ||| CD
subjects  ||| S:467 E:476 ||| NNS
assigned  ||| S:476 E:485 ||| VBN
to  ||| S:485 E:488 ||| TO
an  ||| S:488 E:491 ||| DT
untrained  ||| S:491 E:501 ||| NN
( ||| S:501 E:502 ||| -LRB-
UT ||| S:502 E:504 ||| NNP
)  ||| S:504 E:506 ||| -RRB-
group ||| S:506 E:511 ||| NN
.  ||| S:511 E:513 ||| .
On  ||| S:513 E:516 ||| IN
the  ||| S:516 E:520 ||| DT
experimental  ||| S:520 E:533 ||| JJ
day ||| S:533 E:536 ||| NN
,  ||| S:536 E:538 ||| ,
catheters  ||| S:538 E:548 ||| NNS
were  ||| S:548 E:553 ||| VBD
inserted  ||| S:553 E:562 ||| VBN
in  ||| S:562 E:565 ||| IN
the  ||| S:565 E:569 ||| DT
femoral  ||| S:569 E:577 ||| JJ
artery  ||| S:577 E:584 ||| NN
and  ||| S:584 E:588 ||| CC
vein  ||| S:588 E:593 ||| NN
of  ||| S:593 E:596 ||| IN
one  ||| S:596 E:600 ||| CD
leg  ||| S:600 E:604 ||| NN
for  ||| S:604 E:608 ||| IN
blood  ||| S:608 E:614 ||| NN
sampling  ||| S:614 E:623 ||| NNS
and  ||| S:623 E:627 ||| CC
a  ||| S:627 E:629 ||| DT
bolus  ||| S:629 E:635 ||| NN
of  ||| S:635 E:638 ||| IN
0.3  ||| S:638 E:642 ||| CD
ng  ||| S:642 E:645 ||| FW
LPS ||| S:645 E:648 ||| FW
/ ||| S:648 E:649 ||| FW
kg  ||| S:649 E:652 ||| FW
body  ||| S:652 E:657 ||| NN
wt  ||| S:657 E:660 ||| NNS
was  ||| S:660 E:664 ||| VBD
injected  ||| S:664 E:673 ||| VBN
into  ||| S:673 E:678 ||| IN
an  ||| S:678 E:681 ||| DT
antecubital  ||| S:681 E:693 ||| JJ
vein  ||| S:693 E:698 ||| NN
in  ||| S:698 E:701 ||| IN
the  ||| S:701 E:705 ||| DT
forearm ||| S:705 E:712 ||| NN
.  ||| S:712 E:714 ||| .
Femoral  ||| S:714 E:722 ||| JJ
arterial  ||| S:722 E:731 ||| JJ
blood  ||| S:731 E:737 ||| NN
flow  ||| S:737 E:742 ||| NN
was  ||| S:742 E:746 ||| VBD
measured  ||| S:746 E:755 ||| VBN
by  ||| S:755 E:758 ||| IN
ultrasound  ||| S:758 E:769 ||| JJ
Doppler ||| S:769 E:776 ||| NNP
,  ||| S:776 E:778 ||| ,
and  ||| S:778 E:782 ||| CC
arterial  ||| S:782 E:791 ||| NNS
and  ||| S:791 E:795 ||| CC
venous  ||| S:795 E:802 ||| JJ
blood  ||| S:802 E:808 ||| NN
samples  ||| S:808 E:816 ||| NNS
were  ||| S:816 E:821 ||| VBD
drawn  ||| S:821 E:827 ||| VBN
before  ||| S:827 E:834 ||| IN
( ||| S:834 E:835 ||| -LRB-
Pre ||| S:835 E:838 ||| NNP
)  ||| S:838 E:840 ||| -RRB-
LPS  ||| S:840 E:844 ||| NNP
injection  ||| S:844 E:854 ||| NN
and  ||| S:854 E:858 ||| CC
30 ||| S:858 E:860 ||| CD
,  ||| S:860 E:862 ||| ,
60 ||| S:862 E:864 ||| CD
,  ||| S:864 E:866 ||| ,
90 ||| S:866 E:868 ||| CD
,  ||| S:868 E:870 ||| ,
and  ||| S:870 E:874 ||| CC
120  ||| S:874 E:878 ||| CD
min  ||| S:878 E:882 ||| NN
after  ||| S:882 E:888 ||| IN
the  ||| S:888 E:892 ||| DT
LPS  ||| S:892 E:896 ||| NNP
injection ||| S:896 E:905 ||| NN
.  ||| S:905 E:907 ||| .
Vastus  ||| S:907 E:914 ||| JJ
lateralis  ||| S:914 E:924 ||| JJ
muscle  ||| S:924 E:931 ||| NN
and  ||| S:931 E:935 ||| CC
abdominal  ||| S:935 E:945 ||| JJ
subcutaneous  ||| S:945 E:958 ||| JJ
AT  ||| S:958 E:961 ||| NNP
biopsies  ||| S:961 E:970 ||| NNS
were  ||| S:970 E:975 ||| VBD
obtained  ||| S:975 E:984 ||| VBN
Pre  ||| S:984 E:988 ||| NNP
and  ||| S:988 E:992 ||| CC
60  ||| S:992 E:995 ||| CD
and  ||| S:995 E:999 ||| CC
120  ||| S:999 E:1003 ||| CD
min  ||| S:1003 E:1007 ||| NN
after  ||| S:1007 E:1013 ||| IN
the  ||| S:1013 E:1017 ||| DT
LPS  ||| S:1017 E:1021 ||| NNP
injection ||| S:1021 E:1030 ||| NN
.  ||| S:1030 E:1032 ||| .
LPS  ||| S:1032 E:1036 ||| NNP
increased  ||| S:1036 E:1046 ||| VBD
the  ||| S:1046 E:1050 ||| DT
systemic  ||| S:1050 E:1059 ||| JJ
plasma  ||| S:1059 E:1066 ||| JJ
TNFα  ||| S:1066 E:1071 ||| JJ
and  ||| S:1071 E:1075 ||| CC
IL-6  ||| S:1075 E:1080 ||| CD
level  ||| S:1080 E:1086 ||| NN
as  ||| S:1086 E:1089 ||| IN
well  ||| S:1089 E:1094 ||| RB
as  ||| S:1094 E:1097 ||| IN
the  ||| S:1097 E:1101 ||| DT
TNFα  ||| S:1101 E:1106 ||| JJ
and  ||| S:1106 E:1110 ||| CC
IL-6  ||| S:1110 E:1115 ||| CD
mRNA  ||| S:1115 E:1120 ||| JJ
content  ||| S:1120 E:1128 ||| NN
in  ||| S:1128 E:1131 ||| IN
SkM  ||| S:1131 E:1135 ||| JJ
and  ||| S:1135 E:1139 ||| CC
AT  ||| S:1139 E:1142 ||| NNP
of  ||| S:1142 E:1145 ||| IN
both  ||| S:1145 E:1150 ||| DT
UT  ||| S:1150 E:1153 ||| NNP
and  ||| S:1153 E:1157 ||| CC
T.  ||| S:1157 E:1160 ||| NNP
However ||| S:1160 E:1167 ||| RB
,  ||| S:1167 E:1169 ||| ,
whereas  ||| S:1169 E:1177 ||| IN
the  ||| S:1177 E:1181 ||| DT
LPS-induced  ||| S:1181 E:1193 ||| JJ
inflammatory  ||| S:1193 E:1206 ||| JJ
response  ||| S:1206 E:1215 ||| NN
in  ||| S:1215 E:1218 ||| IN
SkM  ||| S:1218 E:1222 ||| NNP
was  ||| S:1222 E:1226 ||| VBD
enhanced  ||| S:1226 E:1235 ||| VBN
in  ||| S:1235 E:1238 ||| IN
T  ||| S:1238 E:1240 ||| NN
subjects  ||| S:1240 E:1249 ||| NNS
relative  ||| S:1249 E:1258 ||| JJ
to  ||| S:1258 E:1261 ||| TO
UT ||| S:1261 E:1263 ||| NNP
,  ||| S:1263 E:1265 ||| ,
the  ||| S:1265 E:1269 ||| DT
inflammatory  ||| S:1269 E:1282 ||| JJ
response  ||| S:1282 E:1291 ||| NN
systemically  ||| S:1291 E:1304 ||| NNS
and  ||| S:1304 E:1308 ||| CC
in  ||| S:1308 E:1311 ||| IN
AT  ||| S:1311 E:1314 ||| NNP
was  ||| S:1314 E:1318 ||| VBD
somewhat  ||| S:1318 E:1327 ||| RB
delayed  ||| S:1327 E:1335 ||| VBN
in  ||| S:1335 E:1338 ||| IN
T  ||| S:1338 E:1340 ||| NN
subjects  ||| S:1340 E:1349 ||| NNS
relative  ||| S:1349 E:1358 ||| JJ
to  ||| S:1358 E:1361 ||| TO
UT ||| S:1361 E:1363 ||| NNP
.  ||| S:1363 E:1365 ||| .
The  ||| S:1365 E:1369 ||| DT
present  ||| S:1369 E:1377 ||| JJ
findings  ||| S:1377 E:1386 ||| NNS
highlight  ||| S:1386 E:1396 ||| VB
that  ||| S:1396 E:1401 ||| DT
training  ||| S:1401 E:1410 ||| NN
status  ||| S:1410 E:1417 ||| NN
affects  ||| S:1417 E:1425 ||| VBZ
the  ||| S:1425 E:1429 ||| DT
ability  ||| S:1429 E:1437 ||| NN
to  ||| S:1437 E:1440 ||| TO
induce  ||| S:1440 E:1447 ||| VB
a  ||| S:1447 E:1449 ||| DT
LPS-induced  ||| S:1449 E:1461 ||| JJ
acute  ||| S:1461 E:1467 ||| JJ
inflammatory  ||| S:1467 E:1480 ||| JJ
response  ||| S:1480 E:1489 ||| NN
in  ||| S:1489 E:1492 ||| IN
a  ||| S:1492 E:1494 ||| DT
tissue-specific  ||| S:1494 E:1510 ||| JJ
manner ||| S:1510 E:1516 ||| NN
.  ||| S:1516 E:1518 ||| .
